NasdaqGS:RVMDBiotechs
Revolution Medicines (RVMD): Assessing Valuation After New Analyst Coverage and FDA Breakthrough Designations
If you’ve been following Revolution Medicines (RVMD), you know this week brought a flurry of developments that could matter for anyone weighing their next move. Piper Sandler just initiated coverage with a confident nod, while the company itself is touting progress in key Phase 3 trials for daraxonrasib and highlighting two recent FDA Breakthrough Therapy Designations. These milestones are watched closely by biotech investors and signal increased attention from both Wall Street and...